[41] † Correlation of antinuclear antibodies with unfavorable disease course. ‡ 21 additional healthy controls tested negative. § Antitotal IgG as secondary antibody. ¶ Anti-IgG1, IgG2 and ...

Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control ...

(NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is designed to maximize ...

TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...

Sanofi and Teva are closing the gap with positive data on their own anti-TL1A antibody duvakitug. In the phase 2b RELIEVE UCCD trial, duvakitug met the mark in patients with ulcerative colitis (UC ...

Education of doctors at all levels including gastroenterologists on the new possibilities of the laboratory immunodiagnosis of autoimmune liver diseases, so that tests would be appropriately ...

The study presents a potential alternative to adeno-associated virus (AAV)-mediated gene therapy, addressing the exclusion of patients with preexisting anti-AAV antibodies. Severe hemophilia A is ...